Insmed, Inc. (INSM)
Health Care ยท Pharmaceutical Preparations
Insmed, Inc. (INSM) is listed on Nasdaq, where its shares have traded since June 1, 2000. SentiSense covers Insmed, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. William H. Lewis is its chief executive officer. The company reports 1,664 employees, and its corporate website is www.insmed.com.
About Insmed, Inc.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
Latest reported results
Insmed Incorporated reported revenue of $524.4 million for Q3 FY2026, up 268.4% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 653 institutions reported holding INSM, with 223.1 million shares worth $23.8 billion in aggregate. The largest reported holders were Vanguard, FMR and BlackRock. Of the 5 largest reported holders, 3 added shares and 2 reduced their positions during the quarter.
More on INSM
- INSM sentiment: whether news and social coverage of Insmed, Inc. leans bullish or bearish, and the stories driving it.
- INSM ownership: all 653 reporting institutions, plus insider and congressional trades.
- INSM financials: revenue, net income, operating margin and free cash flow through Q3 FY2026.
SentiSense also tracks daily options readings for Insmed, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Insmed, Inc. do?
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare.
What sector is INSM in?
SentiSense classifies Insmed, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does INSM stock trade?
Insmed, Inc. (INSM) is listed on Nasdaq, where its shares have traded since June 1, 2000.
Who is the CEO of Insmed, Inc.?
William H. Lewis is the chief executive officer of Insmed, Inc..